TMS Co.,Ltd.

Rapid Commercialization of Novel Potential Products in the Medical Field

TMS Co.,Ltd.







TMS-007 is a compound which belongs to a family of SMTP compounds. TMS-007 is currently evaluated in Phase II clinical trial for acute ischemic stroke indication at medical facilities including Tohoku University Hospital.
TMS-007 and other SMTP compounds are partnered with Biogen.


Other SMTP Compounds


TMS is developing several other SMTP compounds for indications leveraging their strong anti-inflammatory activities.

Copyright (C) 2008 TMS All Rights Reserved.